Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-06-20T12:21:08.488Z Has data issue: false hasContentIssue false

Chapter 12 - Mood Disorders and Comorbid Substance Use Disorders

Published online by Cambridge University Press:  16 May 2024

By
Michael Weaver ,
Angela M. Heads  and
Louis A. Faillace
Edited by
Allan Young ,
Marsal Sanches ,
Jair C. Soares  and
Mario Juruena
Allan Young
Affiliation:
Institute of Psychiatry, King's College London
Marsal Sanches
Affiliation:
Baylor College of Medicine, Texas
Jair C. Soares
Affiliation:
McGovern Medical School, The University of Texas
Mario Juruena
Affiliation:
King's College London
Get access

Summary

Substance use disorders commonly co-occur with mood disorders (major depression, bipolar disorder) and may be due to the direct effects of illicit substances, such as intoxication and withdrawal, or due to effects stemming from chronic use, including substance-induced mood disorders. Self-medication of mood disorders with legal or illicit substances is highly prevalent. Careful assessment of patients is necessary to determine whether a co-occurring disorder is due to substance use or a separate diagnosis that requires independent treatment. Many depressive symptoms may resolve with treatment of the substance use disorder. Independent mood disorders can be treated with behavioral therapy and standard pharmacological therapy. Some mood disorder medications are also effective for substance use disorders. Some substances that have historically been used recreationally are being studied as possible treatments for mood disorders.

Keywords

substance usesubstance use disordersco-occurring disordersdual diagnosissubstance-induced mood disorderintoxicationwithdrawal
Type
Chapter
Information
Clinical Textbook of Mood Disorders , pp. 125 - 131
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Thornton, LK, Baker, AL, Lewin, TJ, et al. Reasons for substance use among people with mental disorders. Addict Behav. 2012;37(4):427–34.CrossRefGoogle ScholarPubMed
Quello, SB, Brady, KT, Sonne, SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect. 2005;3(1):13–21.CrossRefGoogle ScholarPubMed
Glass, J, Lanctôt, KL, Herrmann, N, Sproule, BA, Busto, UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.CrossRefGoogle ScholarPubMed
Lader, M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295–301.CrossRefGoogle ScholarPubMed
Hajak, G, Müller, W, Wittchen, H-U, Pittrow, D, Kirch, W. Abuse and dependence potential for the non‐benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98(10):1371–8.CrossRefGoogle ScholarPubMed
Rickels, K, Lucki, I, Schweizer, E, Garcia-Espana, F, Case, WG. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol. 1999;19(2):107–13.CrossRefGoogle ScholarPubMed
Jones, CM, Mack, KA, Paulozzi, LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.CrossRefGoogle ScholarPubMed
Weaver, MF. Addiction Treatment. Newburyport, MA: Carlat Publishing, 2017.Google Scholar
Nunes, EV, Quitkin, F, Brady, R, Post-Koenig, T. Antidepressant treatment in methadone maintenance patients. J Addict Dis. 1995;13(3):13–24.CrossRefGoogle Scholar
Nunes, EV, Levin, FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887–96.CrossRefGoogle ScholarPubMed
Weaver, MF, Delos Reyes, C., Schnoll, S. H. Club drug addiction. In Gabbard, GO, editor. Gabbard’s Treatments of Psychiatric Disorders. 5th ed. Washington, DC: American Psychiatric Publishing, 2014; 851–8.Google Scholar
Patton, GC, Coffey, C, Carlin, JB, et al. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195–8.CrossRefGoogle ScholarPubMed
Feingold, D, Weinstein, A. Cannabis and depression. In Murillo-Rodriguez, E, Pandi-Perumal, SR, Monti, JM, editors. Cannabinoids and Neuropsychiatric Disorders. Cham: Springer International, 2021; 67–80.Google Scholar
Lynskey, MT, Glowinski, AL, Todorov, AA, et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry. 2004;61(10):1026–32.CrossRefGoogle ScholarPubMed
Hodgson, K, Almasy, L, Knowles, EE, et al. The genetic basis of the comorbidity between cannabis use and major depression. Addiction. 2017;112(1):113–23.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association Publishing, 2013.Google Scholar
Budney, AJ, Hughes, JR, Moore, BA, Vandrey, R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161(11):1967–77.CrossRefGoogle ScholarPubMed
Weaver, M. Substance-related disorders. In Levenson, JL, editor. The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry. 3rd ed. Washington, DC: American Psychiatric Association Publishing, 2019; 435–62.Google Scholar
Wu, L-T, Ringwalt, CL, Weiss, RD, Blazer, DG. Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use. Drug Alcohol Depend. 2009;104(1–2):156–66.CrossRefGoogle Scholar
Weaver, MF. Hallucinogens. In Levesque, RJ, editor. Encyclopedia of Adolescence. 2nd edition. New York: Springer, 2016.Google Scholar
Lynch, FL, Peterson, EL, Lu, CY, et al. Substance use disorders and risk of suicide in a general US population: a case control study. Addict Sci Clin Pract. 2020;15(1):1–9.CrossRefGoogle Scholar
Derogatis, LR, Unger, R. Symptom Checklist‐90‐Revised. The Corsini Encyclopedia of Psychology. 2010; 1–2.CrossRefGoogle Scholar
Beck, AT, Steer, RA, Brown, G. Beck Depression Inventory–II (BDI-II) [Database record]. APA PsychTests. 1996.CrossRefGoogle Scholar
McLellan, AT, Kushner, H, Metzger, D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213.CrossRefGoogle ScholarPubMed
Pettinati, HM, O’Brien, CP, Dundon, WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23–30.CrossRefGoogle ScholarPubMed
Weaver, M, Schnoll, S. Addiction issues in prescribing opioids for chronic nonmalignant pain. J Addict Med. 2007;1(1):2–10.CrossRefGoogle ScholarPubMed
Weaver, M. Prescribing medications with potential for abuse. J Clin Outcomes Manag. 2009;16(4):171–9.Google Scholar
Weaver, MF. Focus: addiction: prescription sedative misuse and abuse. Yale J Biol Med. 2015;88(3):247.Google Scholar
Katon, W, Sullivan, M, Walker, E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Intern Med. 2001;134(9_Part_2):917–25.CrossRefGoogle ScholarPubMed
Hasin, D, Shmulewitz, D, Stohl, M, et al. Test-retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview. Drug Alcohol Depend. 2020;216:108294.CrossRefGoogle ScholarPubMed
Mann, RE, Zalcman, RF, Smart, RG, Rush, BR, Suurvali, H. Alcohol consumption, Alcoholics Anonymous membership, and homicide mortality rates in Ontario 1968 to 1991. Alcohol Clin Exp Res. 2006;30(10):1743–51.CrossRefGoogle ScholarPubMed
Chang, BP, Kessler, RC, Pincus, HA, Nock, MK. Digital approaches for mental health in the age of COVID-19. BMJ. 2020;369.Google ScholarPubMed
Nunes, EV, Weiss, RD. Co-occurring mood and substance use disorders. In Miller, S, Fiellin, D, Saitz, R, editors. ASAM Principles of Addiction Medicine. 6th ed. Chevy Chase, MD: American Society of Addiction Medicine, 2019; 1360–88.Google Scholar
Kalman, D, Morissette, SB, George, TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106–23.CrossRefGoogle ScholarPubMed
Hughes, JR. How confident should we be that smoking cessation treatments work? Addiction. 2009;104(10):1637–40.CrossRefGoogle ScholarPubMed
Tulloch, HE, Pipe, AL, Clyde, MJ, Reid, RD, Els, C. The quit experience and concerns of smokers with psychiatric illness. Am J Prev Med. 2016;50(6):709–18.CrossRefGoogle ScholarPubMed
Sonne, SC, Brady, KT. Substance abuse and bipolar comorbidity. Psychiatr Clin North Am. 1999;22(3):609–27.CrossRefGoogle ScholarPubMed
Gillman, P. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434–41.CrossRefGoogle ScholarPubMed
Nunes, E, Quitkin, F. Disulfiram and bipolar affective disorder. J Clin Psychopharmacol. 1987;7(4):284.CrossRefGoogle ScholarPubMed
Brackins, T, Brahm, NC, Kissack, JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract. 2011;24(6):541–50.CrossRefGoogle ScholarPubMed
Hysek, CM, Simmler, LD, Nicola, VG, et al. Duloxetine inhibits effects of MDMA (“Ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7(5):e36476.CrossRefGoogle Scholar
Popova, V, Daly, EJ, Trivedi, M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–38.CrossRefGoogle ScholarPubMed
Dos Santos, RG, Bouso, JC, Alcázar-Córcoles, MÁ, Hallak, JE. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11(9):889–902.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×